CASI · Insider Trading
CASI Pharmaceuticals, Inc. Ordinary Shares
Every open-market purchase and sale reported by CASI officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2022-09-09 | Alexander A Zukiwski | EVP and Chief Medical Officer | A | +3,000 deriv. | — |
| 2022-09-08 | James Huang | Director | Buy | +55,573 | +$229.66K |
| 2022-09-02 | James Huang | Director | Buy | +37,196 | +$139.04K |
| 2022-08-26 | James Huang | Director | Buy | +44,527 | +$166.93K |
| 2022-08-23 | James Huang | Director | Buy | +234,221 | +$779.48K |
| 2022-06-17 | Wei-Wu He | Chairman and CEO | Buy | +88,154 | +$272.51K |
| 2022-05-26 | James Huang | Director | A | +397,419 deriv. | — |
| 2022-05-26 | Rajesh C Md Shrotriya | Director | A | +345,806 deriv. | — |
| 2022-05-26 | Franklin Cary Salisbury jr | Director | A | +388,387 deriv. | — |
| 2022-05-26 | Yue Alexander Wu | Director | A | +388,387 deriv. | — |
| 2022-05-26 | Quan Zhou | Director | A | +380,645 deriv. | — |
| 2021-12-06 | Alexander A Zukiwski | Chief Medical Officer | A | −500,000 deriv. | — |
| 2021-11-19 | Wei-Wu He | Chairman and CEO | Buy | +400,000 | +$394.00K |
| 2021-08-20 | Wei-Wu He | Chairman and CEO | Buy | +480,000 | +$613.80K |
| 2021-07-26 | Larry Zhang | President | A | −800,000 deriv. | — |
| 2021-06-16 | James Huang | Director | A | +113,028 deriv. | — |
| 2021-06-16 | Quan Zhou | Director | A | +108,257 deriv. | — |
| 2021-06-16 | Rajesh C Md Shrotriya | Director | A | +98 deriv. | — |
| 2021-06-16 | Franklin Cary Salisbury jr | Director | A | +110,459 deriv. | — |
| 2021-06-16 | Yue Alexander Wu | Director | A | +110,459 deriv. | — |
| 2021-06-16 | Wei-Wu He | Chairman and CEO | A | +4,000,000 deriv. | — |
| 2021-03-30 | Wei-Wu He | Chairman and CEO | Buy | +3,000,000 | +$6.15M |
| 2020-12-23 | Wei-Wu He | Chairman and CEO | G | −380,000 | — |
| 2020-12-18 | Weihao Xu | Chief Financial Officer | Buy | +6,000 | +$15.42K |
| 2020-11-24 | Wei-Wu He | Chairman and CEO | Buy | +227,471 | +$488.24K |
| 2020-07-24 | Larry Zhang | President | Buy | +20,153 | +$38.29K |
| 2020-07-24 | Wei-Wu He | Chairman and CEO | Buy | +4,152,426 | +$7.89M |
| 2020-06-18 | James Huang | Director | A | +70,400 deriv. | — |
| 2020-06-18 | Yue Alexander Wu | Director | A | +68,800 deriv. | — |
| 2020-06-18 | Franklin Cary Salisbury jr | Director | A | +68,800 deriv. | — |
| 2020-06-18 | Quan Zhou | Director | A | +67,429 deriv. | — |
| 2020-06-18 | Rajesh C Md Shrotriya | Director | A | +61,257 deriv. | — |
| 2020-05-21 | Wei-Wu He | Chairman and CEO | Buy | +86,265 | +$194.32K |
| 2020-05-19 | Wei-Wu He | Chairman and CEO | Buy | +438,932 | +$866.64K |
| 2020-03-30 | Wei-Wu He | Chairman and CEO | Buy | +6,880 | +$14.31K |
| 2020-03-27 | Wei-Wu He | Chairman and CEO | Buy | +524,493 | +$1.07M |
| 2020-03-19 | Wei-Wu He | Chairman and CEO | Buy | +1,000,002 | +$1.53M |
| 2020-01-06 | Wealth Strategy Holding Ltd | 10%+ Owner | X | +493,827 | +$834.57K |
| 2019-12-18 | Wei-Wu He | Chairman and CEO | X | +374,321 | +$632.60K |
| 2019-12-17 | Alexander A Zukiwski | Chief Medical Officer | A | −200,000 deriv. | — |
| 2019-09-24 | Larry Zhang | President | A | −200,000 deriv. | — |
| 2019-08-20 | Wei-Wu He | Chief Executive Officer | Buy | +20,000 | +$64.00K |
| 2019-08-15 | Wei-Wu He | Chief Executive Officer | Buy | +160,000 | +$507.20K |
| 2019-06-21 | Ken Keyong Ren | Director | A | +51,538 deriv. | — |
| 2019-06-21 | Wei-Wu He | CEO | A | +4,000,000 deriv. | — |
| 2019-06-21 | James Huang | Director | A | +59,231 deriv. | — |
| 2019-06-21 | Rajesh C Md Shrotriya | Director | A | +51,538 deriv. | — |
| 2019-06-21 | Franklin Cary Salisbury jr | Director | A | +57,885 deriv. | — |
| 2019-06-21 | Yue Alexander Wu | Director | A | +57,885 deriv. | — |
| 2019-06-21 | Quan Zhou | Director | A | +56,731 deriv. | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the CASI quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.